Vivimed Labs Limited (VIVIMEDLAB) — Financial Results

Investor Takeaways

Revenue declined 15.6% YoY to ₹36.51 Cr in Q3FY25 from [amount not verified] in Q4FY24, with net loss widening to [amount context mismatch] Cr versus ₹5.26 Cr profit in the prior quarter.

Quarterly operating profit margin turned negative at 2.9% in Q3FY25, compared to -73.72% in Q4FY24, indicating improved cost control despite persistent losses.

No financial metrics were disclosed in the filing; all performance data is derived solely from the provided quarterly trend figures.

Overall Tone: Neutral

Key Financial Highlights

Metric	Value	YoY Change
Revenue	₹36.51 Cr	-15.6%
Net Profit	₹-5.97 Cr	N/A
EBITDA	N/A	N/A
EPS	₹-0.72	N/A
OPM	2.9%	N/A

What Changed

The filing confirms Vivimed Labs Limited's audited FY2026 financial results were published in major newspapers on July 22, 2026, following Board approval on July 17, 2026. The announcement explicitly states no financial metrics were disclosed in this public notice, with all performance data restricted to the provided quarterly trend figures. The company also proposed voluntary delisting via postal ballot and referenced administrative matters including civil petitions and tender opportunities, but these do not impact financial metrics. Quarterly revenue declined to ₹36.51 Cr in Q3FY25 from [amount not verified] in Q4FY24, while net profit shifted from a ₹5.26 Cr profit in Q4FY24 to a ₹5.97 Cr loss. Operating profit margin improved to 2.9% from -73.72% in the prior quarter, though the company remains loss-making. The filing emphasizes regulatory updates and strategic options over financial transparency, making it impossible to assess growth prospects or near-term financial health from the disclosed information.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Vivimed Labs	-4.43	N/A	N/A	61.27
Sun Pharma	41.28	15.11%	20.34%	4,50,643.09
Divi's Labs	72.41	16.56%	22.09%	1,79,470.03
Torrent Pharma	80.06	N/A	N/A	1,49,108.91

Vivimed Labs trades at a negative P/E ratio compared to peers' positive P/E ratios, indicating un profitability, while its peers demonstrate strong ROE and ROCE metrics.

Risks & Concerns

The company remains loss-making with no disclosed path to profitability, as evidenced by consecutive quarterly losses and negative EPS.

No financial metrics were provided in the filing, preventing assessment of revenue trends, margin stability, or cash flow health.

The negative P/E ratio (-4.43) signals market skepticism about near-term earnings recovery.

Quarterly Trend

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	OPM%
Q3FY25	36.51	-5.97	2.9%
Q2FY25	24.77	-5.14	-2.58%
Q1FY25	29.37	-8.19	-13.42%
Q4FY24	38.62	5.26	-73.72%

📄 View Original Announcement (PDF)

📊 Stock Analysis — VIVIMEDLAB ✨ Ask AI About This

About Vivimed Labs Limited (VIVIMEDLAB)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹61.27 Cr P/E: -4.4

View full VIVIMEDLAB stock details →

📡 Get AI alerts when VIVIMEDLAB files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track VIVIMEDLAB — Free

💡 Ask AI about this filing

"When will the audited financial results for FY2026 be publicly available?" "What is the current share price and trading volume for VIVIMEDLAB?" "How does the delisting proposal impact shareholder voting rights and exit options?"

Ask AI Free →

📊 More VIVIMEDLAB filings

See all VIVIMEDLAB filings →

🔥 Also filed on 22 July 2026

SPLIL SPL Industries Limited Annual Report SIS SIS LIMITED Financial Results JAGSNPHARM Jagsonpal Pharmaceuticals Limited Financial Results PIRAMALFIN Piramal Finance Limited Financial Results HBSL HB Stockholdings Limited Annual Report VIJAYA Vijaya Diagnostic Centre Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when VIVIMEDLAB files new disclosures

Track VIVIMEDLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track VIVIMEDLAB — Free

Free account · 2 AI queries/day